Primenenie Mildronata u patsientov s tserebrovaskulyarnoy patologiey
- Autores: Bakunts G.O1, Bagdasaryan K.F1
-
Afiliações:
- Edição: Nº 10 (2015)
- Páginas: 45-48
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288010
- ID: 288010
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article presents the results of the evaluation of the effect of Mildronate at a daily dose of 500 mg (intravenously) as a part of basic therapy during the first 10 days of treatment, and at a daily dose of 1000 mg (orally) for 4 weeks on cognitive performance, coagulation and lipid profiles of 63 patients with cerebral discirculations. It was shown that study group had significantly lower lipid levels and better normalization of hemostatic parameters compared to control group, which were reflected on neurological characteristics of patients.
Texto integral
Bibliografia
- Бакунц Г.О. Эндогенные факторы церебрального инсульта. М., 2011. 360 с.
- Верещагин Н.В. Недостаточность кровообращения в вертебро-базилярной системе. Consilium Medicum. 2003;52:56-61.
- Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М., 2001. 328 с.
- Гусев Е.И., Скворцова В.И., Платонова И.А. Терапия ишемического инсульта. Consilium Medicum. 2003;5:8-16.
- Дамулин И.В., Коберская Н.Н., Антоненко Л.М. Влияние Милдроната на когнитивные нарушения при дисциркуляторной энцефалопатии. Неврологический журнал. 2006;а(1):1-6.
- Логина И.П., Калвиньш И.Я. Милдронат в неврологии. Рига, 2012. 54 с.
- Скворцова В.И., Евзельман М.А. Ишемический инсульт. Орел, 2006. 404 с.
- The European Stroke Initiative Committee and the EUSI Writing Committee. European stroke initiative recommendations for stroke management - update 2003. Cerebrovascular Disease. 2003;16:311-37.
Arquivos suplementares
